MARKET

CLSN

CLSN

Celsion
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9926
-0.0174
-1.72%
Opening 11:17 09/23 EDT
OPEN
1.010
PREV CLOSE
1.010
HIGH
1.010
LOW
0.9850
VOLUME
168.03K
TURNOVER
--
52 WEEK HIGH
3.480
52 WEEK LOW
0.4305
MARKET CAP
85.92M
P/E (TTM)
-2.1346
1D
5D
1M
3M
1Y
5Y
BRIEF-Celsion, Hainan Poly Pharm Sign Agreement to Manufacture Celsion’s DNA-based Vaccine
reuters.com · 6d ago
Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion’s DNA-based Vaccine
Expands GEN-1 Program Collaboration to Add Clinical and Commercial Batches of Investigational Vaccine LAWRENCEVILLE, N.J. and HAINAN, China, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-base...
GlobeNewswire · 6d ago
Celsion, Hainan Poly Pharm Agree to Jointly Manufacture Celsion's DNA-Based COVID-19 Vaccine
MT Newswires · 6d ago
Celsion (CLSN) COVID Vaccine Effective in Pre-Clinical Studies
Zacks.com · 09/03 16:40
Celsion's Vaccine Platform Shows Potential Against COVID-19 In Preclinical Studies
Benzinga · 09/02 14:02
BRIEF-Celsion Reports Immune Response From In Vivo Studies With Its PLACCINE DNA Vaccine Platform
reuters.com · 09/02 12:15
Celsion Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine Platform
Results Indicate Induction of Adaptive Immune Response Against SARS-CoV-2 Company Plans Additional Development Work to Further Optimize its Vaccine Platform Through Vector Compositions, Delivery Route, Dosing and Dosing Frequency, and Use of Molecular Adju...
GlobeNewswire · 09/02 12:00
Is Celsion (NASDAQ:CLSN) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Simply Wall St. · 08/14 09:02
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLSN. Analyze the recent business situations of Celsion through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLSN stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 57
Institutional Holdings: 9.08M
% Owned: 10.49%
Shares Outstanding: 86.56M
TypeInstitutionsShares
Increased
13
1.04M
New
9
887.60K
Decreased
7
447.75K
Sold Out
12
4.31M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.88%
Pharmaceuticals & Medical Research
+1.19%
Key Executives
Chief Financial Officer/Senior Vice President/Secretary/IR Contact Officer
Jeffrey Church
Executive Vice President
Khursheed Anwer
Senior Vice President
Nicholas Borys
Director/Chief Executive Officer/President/Chairman
Michael Tardugno
Director
Stacy Lindborg
Director
Christine Pellizzari
Independent Director
Donald Braun
Independent Director
Pok Yu Chow
Independent Director
Frederick Fritz
Independent Director
Robert Hooper
Independent Director
Andreas Voss
No Data
About CLSN
Celsion Corporation (Celsion) is a clinical stage biotechnology company. The Company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer and ThermoDox, a heat-activated liposomal encapsulation of doxorubicin for several cancer indications. Its GEN-1, an IL-12 DNA plasmid vector formed into nanoparticles with a lipopolymeric delivery system, is the product candidate designed via the TheraPlas platform technology. Its Lysolipid Thermally Sensitive Liposomes (LTSL) technology is a heat-sensitive liposomal formulation that targets disease with therapeutics in the presence of mild heat. Its TheraSilence technology delivers synthetically generated inhibitory RNA (RNAi) to regulate protein expression in target cells.

Webull offers kinds of Celsion Corporation stock information, including NASDAQ:CLSN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLSN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLSN stock methods without spending real money on the virtual paper trading platform.